Driving Breakthroughs in Healthcare, One Bold Idea at a Time

Featured

Genesys Capital is closing its largest fund to date – Genesys Ventures IV LP

Latest

World’s First Wearable Doppler Ultrasound Patch Expands to East Coast to Enhance Patient Safety at The Mount Sinai Hospital

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

All Articles

04 November 2024

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

31 October 2024

Feldan Therapeutics announces the treatment of the first patient in the phase 1/2a clinical trial of its candidate fld-103, against Basal Cell Carcinoma

30 October 2024

Kapoose Creek Bio Acquires Exclusive License to Adapsyn Bioscience’s World-Leading AI Technology for Drug Development

20 September 2024

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

04 September 2024

Feldan Therapeutics Completes a US$ 21 Million Series B financing co-led by Genesys Capital and Fonds de Solidarité Ftq

Two Genesys co-creations listed on Fierce's Top 10 smartest deals in biopharma